4-Amino-6-(2-methyl-2-propanyl)-3-thioxo-3,4-dihydro-1,2,4-triazi n-5(2H)-one

We are 4-Amino-6-(2-methyl-2-propanyl)-3-thioxo-3,4-dihydro-1,2,4-triazi n-5(2H)-one CAS:57989-76-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Related News: International Chemical Investors Group (ICIG) recently announced it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation.(Z)-2-(2-Aminothiazol-4-yl)-2-(tert-butoxycarbonylmethoxyimino)acetic acid CAS:74440-02-1 Among the APIs we produce, there is an API which passes through over ten kinds of intermediates in a process when it changes from being a raw material into an API.2-chloro-N-(oxomethylidene)benzenesulfonamide CAS:64900-65-8 At the same time, because the profits of a single variety of characteristic APIs do not have long-term growth, companies need more product reserves.873-74-5 At the same time, due to the increase in production costs and environmental protection cost pressures in Europe and the United States, as well as the improvement of process technology, production quality, and registration and certification capabilities of China’s bulk drug manufacturers, bulk drug companies have accelerated their transfer to China, and the bulk drug industry in China has produced Scale continues to increase.ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment’s chemistry, manufacturing and controls process, but not its safety.